Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
François DozCornelis M van TilburgBirgit GeoergerMartin HøjgaardIngrid ØraValentina BoniMichael CapraJulia ChisholmHyun Cheol ChungSteven G DuBoisSoledad Gallego-MelconNicolas U GerberHiroaki GotoJuneko E Grilley-OlsonJordan R HansfordDavid S HongAntoine ItalianoHyoung Jin KangKarsten NysomAnne ThorwarthJoanna StefanowiczMakato TaharaDavid S ZieglerIgor T GavrilovicRicarda NorenbergLaura DimaEsther De La CuestaTheodore W LaetschAlexander E DrilonSebastien PerreaultPublished in: Neuro-oncology (2021)
In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.
Keyphrases